Thermo Fisher Scientific to Invest $24 Million to Expand Global Bioproduction Capabilities
The company will invest $24 million into its Inchinnan, Scotland, site to expand global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell-culture media.
Thermo Fisher Scientific announced it will invest $24 million into its Inchinnan, Scotland, site to expand global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell-culture media, according to a Nov. 5, 2019 company press release.
"More and more customers are outsourcing their liquid manufacturing to ensure the highest quality while delivering efficiency," said Cory Stevenson, president of Thermo Fisher's bioproduction business, in the press release. "This investment will expand capabilities and expertise at our existing cell-culture manufacturing center of excellence in the UK to meet growing customer demand for our industry-leading bioproduction products."
The expansion is set to be complete by June 2021.
Source: Thermo Fisher Scientific
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
